Roivant Sciences Ltd.
ROIV
$36.36
$0.060.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.44M | 2.52M | 2.00M | 1.57M | 2.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.44M | 2.52M | 2.00M | 1.57M | 2.17M |
| Cost of Revenue | 202.30M | 199.27M | 166.08M | 164.18M | 153.07M |
| Gross Profit | -200.86M | -196.75M | -164.08M | -162.61M | -150.90M |
| SG&A Expenses | 165.53M | 173.07M | 175.05M | 129.53M | 131.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 367.83M | 372.33M | 341.13M | 293.70M | 284.98M |
| Operating Income | -366.39M | -369.81M | -339.14M | -292.13M | -282.81M |
| Income Before Tax | -294.56M | 454.10M | -290.37M | -159.04M | -269.26M |
| Income Tax Expenses | -3.96M | 98.35M | 23.33M | 7.00M | 4.65M |
| Earnings from Continuing Operations | -290.61M | 355.74M | -313.70M | -166.04M | -273.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 100.77M | -52.75M | 47.81M | 52.52M | 50.56M |
| Net Income | -189.84M | 302.99M | -265.89M | -113.52M | -223.36M |
| EBIT | -366.39M | -369.81M | -339.14M | -292.13M | -282.81M |
| EBITDA | -365.79M | -369.17M | -338.44M | -291.21M | -281.71M |
| EPS Basic | -0.26 | 0.43 | -0.38 | -0.17 | -0.33 |
| Normalized Basic EPS | -0.15 | -0.36 | -0.21 | -0.17 | -0.15 |
| EPS Diluted | -0.26 | 0.28 | -0.38 | -0.17 | -0.33 |
| Normalized Diluted EPS | -0.15 | -0.31 | -0.21 | -0.17 | -0.15 |
| Average Basic Shares Outstanding | 720.78M | 702.13M | 696.86M | 680.95M | 680.29M |
| Average Diluted Shares Outstanding | 720.78M | 812.29M | 696.86M | 680.95M | 680.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |